ReceptorBio Licenses Telik’s Diabetes Program
This article was originally published in The Pink Sheet Daily
Executive Summary
Ex-Telik exec teams with Bay Area diabetes experts to develop insulin receptor activators.
You may also be interested in...
Troubled Biotechs: Orexigen, Telik, Trubion
Vanda’s recent good news gives U.S. biotechs hope for a turnaround, while BIO’s Greenwood predicts most will survive the credit crunch.
Troubled Biotechs: Orexigen, Telik, Trubion
Vanda’s recent good news gives U.S. biotechs hope for a turnaround, while BIO’s Greenwood predicts most will survive the credit crunch.
Angiomax “Not Approvable” For Acute Coronary Syndromes
The Medicines Company says FDA letter is "vague"; concerns pertain to non-inferiority design for ACUITY trial.